We also recently demonstrated that high COX-2 expression in tumour cells can identify cervical cancer patients with a poor chance of response to neoadjuvant chemotherapy and worse prognosis (Ferrandina et al, 2002b). The gene discussed is PTGS2; the disease is cervical carcinoma.